Compare uniQure N.V. Ordinary Shares (QURE) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Viasat — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Viasat trades at $60.97 (market cap $9.21B). The key difference: Viasat is far larger — about 6.2× uniQure N.V. Ordinary Shares's market cap, and Viasat is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Viasat for 8 Days on average.
| QURE | VSAT | |
|---|---|---|
Market Cap | $1.48B | $9.21B |
Volume | 2,488,780 | 1,494,317 |
Sector | Health | Technology |
52-Week High | $70.59 | $89.81 |
52-Week Low | $9.03 | $30.35 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $728.62M | $14.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VSAT trades at $66.9, down 1.12% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $574.96 million in 2025, though revenue grew to $4.52 billion. Recent positive developments include the ViaSat-3 F2 and F3 satellites entering service and a $1 billion joint venture with Space42 to create Equatys for direct-to-device connectivity, signaling growth potential in government and commercial markets.
The outlook is mixed; analyst consensus is a Buy with a $94.29 price target, but near-term profitability challenges and high debt levels pose risks. The stock's investment case hinges on execution of new contracts and satellite deployments driving future earnings growth beyond current losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
